[{"id":"8163efc5-651e-4b22-8baf-20113d9df6f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05336721","created_at":"2022-04-20T16:53:48.712Z","updated_at":"2024-07-02T16:36:11.782Z","phase":"Phase 2","brief_title":"A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC","source_id_and_acronym":"NCT05336721","lead_sponsor":"Chipscreen Biosciences, Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Auraza (chiauranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 03/15/2024","primary_completion_date":" 03/15/2024","study_txt":" Completion: 08/09/2024","study_completion_date":" 08/09/2024","last_update_posted":"2022-04-20"},{"id":"293aa130-f843-4e6e-b244-1c52e1d1dad3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324830","created_at":"2021-01-18T05:23:43.525Z","updated_at":"2024-07-02T16:37:04.485Z","phase":"Phase 1a/1b","brief_title":"Monotherapy Dose Finding With BI 847325 in Solid Tumours","source_id_and_acronym":"NCT01324830","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • RAS mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 847325"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 04/15/2011","start_date":" 04/15/2011","primary_txt":" Primary completion: 06/06/2013","primary_completion_date":" 06/06/2013","study_txt":" Completion: 10/10/2013","study_completion_date":" 10/10/2013","last_update_posted":"2018-12-21"}]